Collectively, the study provides compelling evidence that CHK1-targeted therapies, especially in combination with PARP inhibitors, may represent an effective strategy for the treatment of gastric cancer, irrespective of TP53 mutational status [117]. This evidence concerns the gene TP53 and gastric cancer.